Comment: Pfizer-Arena deal has overlaps in inflammation but differing mechanisms of action could mitigate competition issues
Pfizer’s proposed $6.7 billion acquisition of Arena creates overlaps in its inflammation and immunology portfolio that could draw scrutiny from the US Federal Trade Commission. However, the companies can argue that...To view the full article, register now.
Already a subscriber? Click here to view full article